吡喹酮
生物
血吸虫病
免疫系统
药品
药理学
作用机理
体内
机制(生物学)
计算生物学
免疫学
癌症研究
生物信息学
体外
蠕虫
遗传学
哲学
认识论
作者
Ranielly Araújo Nogueira,Maria Gabriela Sampaio Lira,Irlla Correia Lima Licá,Gleycka Cristine Carvalho Gomes,Vitor Augusto Ferreira dos Santos,Antonio Camilo Correia Mendes Filho,João Gustavo Mendes Rodrigues,Guilherme Silva Miranda,Rafael Cardoso Carvalho,Flávia Raquel Fernandes do Nascimento
标识
DOI:10.1016/j.molbiopara.2022.111531
摘要
Praziquantel (PZQ) is the drug of choice for the treatment of all forms of schistosomiasis, although its mechanisms of action are not completely understood. PZQ acts largely on adult worms. This narrative literature review describes what is known about the mechanisms of action of PZQ against schistosomes from in vitro and in vivo studies and highlights the molecular targets in parasites and immune responses induced in definitive hosts by this drug. Moreover, new therapeutic uses of PZQ are discussed. Studies have demonstrated that in addition to impacting voltage-operated Ca2 + channels, PZQ may interact with other schistosome molecules, such as myosin regulatory light chain, glutathione S-transferase, and transient receptor potential channels. Following PZQ administration, increased T regulatory type 1 (Tr1) cell differentiation and decreased inflammation were observed, indicating that PZQ promotes immunoregulatory pathways. Although PZQ is widely used in mass drug administration schemes, the existence of resistant parasites has not been proven; however, it is a concern that should be constantly investigated in human populations. In addition, we discuss studies that evaluate health applications of PZQ (other than helminth infection), such as its effect in cancer therapy and its adjuvant action in vaccines against viruses.
科研通智能强力驱动
Strongly Powered by AbleSci AI